MedTrace Logo

Prevention of Clostridium Difficile-associated Diarrhea by Daily Intake of Kefir

NCT02707198 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 2

Last updated 2022-05-19

Study results available
· View outcomes & findings →

Summary

This study is being conducted to investigate the potential benefits of probiotic intake for preventing antibiotic associated diarrhea and Clostridium difficile infection in patients undergoing a systemic antibiotic treatment. The primary research question is: can daily intake of kefir, a yogurt-like food containing probiotics, reduce the incidence of diarrhea and Clostridium difficile infection in patients during antibiotic treatment?

Conditions

  • Clostridium Difficile Infection
  • Diarrhea

Interventions

DRUG

kefir

4 ounces of kefir 3 times a day, with or without food.

Sponsors & Collaborators

  • St. Luke's Hospital of Duluth

    lead OTHER

Principal Investigators

  • Johan S Bakken, M.D., Ph.D. · St. Luke's Hospital of Duluth

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
NONE
Model
FACTORIAL

Eligibility

Min Age
19 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-11-30
Primary Completion
2019-05-10
Completion
2019-05-10

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02707198 on ClinicalTrials.gov